# A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

> **NCT03290950** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 75 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** daratumumab
- **DRUG:** carfilzomib
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT03290950
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-25
- **Primary completion:** 2025-05-21
- **Final completion:** 2026-09
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03290950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03290950, "A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03290950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*